Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Stock Chart & Stats
$217.11
-$1.97(-1.10%)
At close: 4:00 PM EST
$217.11
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$164.39 - $244.81
Previous CloseN/A
Volume1.02M
Average Volume (3M)5.74M
Market Cap
$383.72B
Enterprise Value$450.12B
Total Cash (Recent Filing)$5.67B
Total Debt (Recent Filing)$68.74B
Price to Earnings (P/E)91.1
Beta0.24
Next Earnings
Apr 24, 2026EPS Estimate
3.03Next Dividend Ex-DateN/A
Dividend Yield2.87%
Share Statistics
EPS (TTM)2.71
Shares Outstanding1,767,384,600
10 Day Avg. Volume6,773,853
30 Day Avg. Volume5,743,463
Financial Highlights & Ratios
PEG Ratio-6.08
Price to Book (P/B)94.54
Price to Sales (P/S)5.58
P/FCF Ratio17.63
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue7.55
Enterprise Value/Gross Profit10.82
Enterprise Value/Ebitda35.18
Forecast
1Y Price Target
$252.71Price Target Upside16.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsEarnings and revenue beat consensus expectations, driven by strong commercial execution of core brands, reinforcing analyst optimism on near-term financial momentum.
Immunology Growth PotentialSkyrizi and Rinvoq maintain leading market positions with potential indication expansions that analysts view as meaningful drivers of future sales growth.
Neuroscience PerformanceNeuroscience portfolio strength, led by Parkinson's treatments and accelerating Vyalev sales, supports diversified revenue growth beyond immunology.
Bears Say
Competitive Pressure In ImmunologyRising competition from rival therapies, including share gains by Tremfya and potential oral IL‑23 alternatives, could erode market share for Skyrizi and Rinvoq and pressure sales trajectories.
Light Late-stage PipelinePipeline lacks significant late‑stage assets, leaving growth dependent on lifecycle management and indication expansions rather than new launch catalysts, which may limit near-term upside.
Reduced Commercial VisibilityManagement's decision to stop mid‑cycle commercial updates for key immunology brands reduces interim visibility and makes it harder for investors to assess ongoing sales trends.
AbbVie News
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $164.39 and its highest was $244.81 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $383.72B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 24, 2026 which is in 77 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Feb 04, 2026. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.653 by $0.057.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.87%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.03.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,384,600 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.71 in its last earnings report, beating expectations of $2.653. Following the earnings report the stock price went down -3.789%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$252.71 (16.40% Upside)
$252.71 (16.40% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 87%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 410.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 85%
Bearish news 15%
Bearish news 15%
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad operational strength: record sales, multiple high‑growth franchises (notably SKYRIZI, RINVOQ, and neuroscience brands), significant R&D and BD investments, and an optimistic 2026 financial outlook (≈9.5% revenue growth, EPS guidance and margin expansion). Headwinds were clearly disclosed — substantial HUMIRA erosion, declines in IMBRUVICA and parts of aesthetics, acquired IPR&D charges compressing near‑term margins, and modest pricing pressure on key immunology assets — but management articulated clear mitigation levers (strong portfolio growth, new approvals, pipeline catalysts, BD additions, and a large free cash flow profile). Overall, positive execution and outlook outweigh the listed challenges.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$252.71
▲(16.40% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
19.79% Mutual Funds
― Other Institutional Investors
57.47% Public Companies and Individual Investors